US009187559B2

(12) **United States Patent**
Hoffman et al.

(10) **Patent No.: US 9,187,559 B2**
(45) **Date of Patent: *Nov. 17, 2015**

(54) **MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING IDIOPATHIC INFLAMMATORY BOWEL DISEASE**

(71) Applicant: **AbbVie Biotechnology Ltd**, Hamilton (BM)

(72) Inventors: **Rebecca S. Hoffman**, Wilmette, IL (US); **Elliot K. Chartash**, Randolph, NJ (US); **Lori K. Taylor**, Wadsworth, IL (US); **George R. Granneman**, Lindenhurst, IL (US); **Philip Yan**, Vernon Hills, IL (US)

(73) Assignee: **AbbVie Biotechnology Ltd**, Hamilton (BM)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/628,068**

(22) Filed: **Feb. 20, 2015**

(65) **Prior Publication Data**

US 2015/0175690 A1 Jun. 25, 2015

Related U.S. Application Data

(63) Continuation of application No. 14/229,664, filed on Mar. 28, 2014, now Pat. No. 8,961,973, which is a continuation of application No. 11/104,117, filed on Apr. 11, 2005, now Pat. No. 8,889,136.

(60) Provisional application No. 60/569,100, filed on May 7, 2004, provisional application No. 60/561,710, filed on Apr. 12, 2004, provisional application No. 60/561,139, filed on Apr. 9, 2004.

(51) **Int. Cl.**

A61K 39/395	(2006.01)
C07K 16/24	(2006.01)
A61K 39/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/241*** (2013.01); ***A61K 39/3955*** (2013.01); *A61K 2039/505* (2013.01); *A61K 2039/545* (2013.01); *C07K 2316/96* (2013.01); *C07K 2317/21* (2013.01); *C07K 2317/56* (2013.01); *C07K 2317/565* (2013.01); *C07K 2317/76* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,231,024	A	7/1993	Moeller et al.
5,654,407	A	8/1997	Boyle et al.
5,795,967	A	8/1998	Aggarwal et al.
5,859,205	A	1/1999	Adair et al.
5,877,293	A	3/1999	Adair et al.
5,929,212	A	7/1999	Jolliffe et al.
5,994,510	A	11/1999	Adair et al.
6,090,382	A	7/2000	Salfeld et al.
6,214,870	B1	4/2001	McClure et al.
6,235,281	B1	5/2001	Stenzel et al.
6,258,562	B1	7/2001	Salfeld et al.
6,270,766	B1	8/2001	Feldman et al.
6,509,015	B1	1/2003	Salfeld et al.
6,732,589	B2	5/2004	Eickhoff et al.
7,223,394	B2	5/2007	Salfeld et al.
7,250,165	B2	7/2007	Heavner et al.
7,541,031	B2	6/2009	Salfeld et al.
7,588,761	B2	9/2009	Salfeld et al.
7,863,426	B2	1/2011	Wan et al.
7,919,264	B2	4/2011	Maksymowych et al.
8,034,906	B2	10/2011	Borhani et al.
8,092,998	B2	1/2012	Stuhlmuller et al.
8,093,045	B2	1/2012	Pia et al.
8,187,836	B2	5/2012	Hsieh et al.
8,197,813	B2	6/2012	Salfeld et al.
8,206,714	B2	6/2012	Salfeld et al.
8,216,583	B2	7/2012	Kruase et al.
8,231,876	B2	7/2012	Wan et al.
8,372,400	B2	2/2013	Salfeld et al.
8,372,401	B2	2/2013	Salfeld et al.
8,414,894	B2	4/2013	Salfeld et al.
8,420,081	B2	4/2013	Fraunhofer et al.
8,436,149	B2	5/2013	Borhani et al.
8,889,136	B2 *	11/2014	Hoffman et al. 424/145.1
8,961,973	B2 *	2/2015	Hoffman et al. 424/145.1
8,961,974	B2 *	2/2015	Hoffman et al. 424/145.1
9,061,005	B2 *	6/2015	Hoffman et al. 1/1

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2243459	8/1997
CA	2 803741	1/2004

(Continued)

OTHER PUBLICATIONS

Jenkins et al., J Clin Pathol. Feb. 1997;50(2):93-105.*

Probert et al., Gut 2003;52:998-1002.*

Gornet et al., Aliment Pharmacol Ther 2003; 18: 175-181.*

Geboes, Karel. "Histopathology of Crohn's disease and ulcerative colitis." Inflammatory Bowel Disease. Edinburgh, London, Melbourne: Churchill Livingstone (2003): 255-276.*

(Continued)

Primary Examiner — Zachary Skelding

(74) *Attorney, Agent, or Firm* — Ropes & Gray LLP; Karen Mangasarian; Qianru Li

(57) **ABSTRACT**

Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.

30 Claims, 10 Drawing Sheets